Slides
Page 1
1 NASDAQ: CRBP @corbuspharmawww.corbuspharma.com Connecting Innovation to Purpose Corporate Presentation September 14, 2026
Page 2
2 2 This presentation contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act of 1995, as amended, including those relating to the Company’s trial results, product development, clinical and regulatory timelines, including timing for completion of trials and presentation of data, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities, sufficiency of cash runway and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions. These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors on our operations, clinical development plans and timelines, which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s filings with the Securities and Exchange Commission, including those described in our Annual Report on Form 10-K for the year ended December 31, 2025. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this presentation. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. This presentation includes limited observations derived from separate clinical settings that are not, and should not be interpreted as, direct or indirect head-to-head comparisons of CRB-701 or CRB-913 with any other product. The observations described herein are subject to change as additional data become available, and future clinical trials of CRB-701 or CRB-913 may not reproduce, validate, or otherwise confirm these observations. All product names, logos, brands and company names are trademarks or registered trademarks of their respective owners. Their use does not imply affiliation or endorsement by these companies. Forward-Looking Statements
Page 3
3 3 OBESITY Differentiated portfolio in Oncology and Obesity Overview Oncology Nectin 4 ADC – OPSCC (lead), cervical cancer • Promising Phase 1/2 2L data: 43% ORR at 3.6 mg/kg in OPSCC • Registrational 2L OPSCC study (TEMPO-1) underway • CRB-701 + pembrolizumab data in 1L OPSCC in Q1 2027 • Potential BLA filing in 2L OPSCC in mid 2028 • Large TAM: ~14k 2L OPSCC eligible patients Obesity Peripherally restricted CB1 inverse agonist for obesity • Competitive 5% placebo adjusted weight loss in Phase 1b at 12 weeks • Favorable emerging safety and tolerability profile • Phase 2 monotherapy study expected to start 1H 2027 • > 1 billion people worldwide living with obesity Pipeline of promising clinical assets targeting large commercial opportunities with significant unmet needs CRB-701 CRB-913
Page 4
4 4 Focused and diversified pipeline Therapy Mechanism of Action Indication (rights) Pre-Clinical Phase 1 Phase 2 Phase 3 Milestones CRB-701 Nectin-4 ADC positive solid tumors 2L OPSCC (US + Europe) First patient expected to be dosed in TEMPO-1 in Sept. 2026 1L OPSCC (US + Europe) Topline ORR data expected in Q1 2027 Cervical (US + Europe) Broad alignment with the FDA on registrational study CRB-913 Highly peripherally- restricted CB1 inverse agonist Obesity (Global) Phase 2 monotherapy study expected to commence 1H 2027 FDA Fast Track Designation granted HNSCC and Cervical $118M Cash, cash equivalents & investments as of June 30, 2026: approximately 18.7M common shares issued and outstanding (~22.4M fully diluted shares) PIPELINE FDA Fast Track Designation granted HNSCC and Cervical
Page 5
5 CRB-701 Next-Generation Nectin-4 ADC targeting oropharyngeal (OPSCC) and cervical cancers
Page 6
6 6 CRB-701 DAY 1 1.25 mg/kg DAY 8 1.25 mg/kg DAY 15 1.25 mg/kg DAY 22 dose holiday DAY 28 DAY 1 CRB- 701 DAY 8 dose holiday DAY 15 dose holiday DAY 22 CRB-701: Reimagining the next-generation Nectin-4 ADC Novel Nectin-4 Antibody ADCC + CDC functionality Glutamine Focused Side Chain Conjugation Payload: MMAE Microtubule Disruption Cathepsin-B Cleavage Site Precise & stable DAR of 2 2x internalization vs. PADCEV® Reduced free MMAE STRUCTURE
Page 7
7 7 CRB-701-01 Study design (U.S. and Europe) Dose Optimization (Project Optimus): HNSCC & cervical Dose escalation Dose escalation/ de-escalation decisions were made based on the occurrence of DLTs CRB-701 + pembrolizumab data expected in Q1 2027 Dose levels in part B were defined by the pharmacologically active dose range identified in part A 1.8 mg/kg Q3W 21-day observation 2.7 mg/kg Q3W 21-day observation 3.6 mg/kg Q3W 21-day observation 4.5 mg/kg Q3W 21-day observation RANDOMIZATION 2.7 mg/kg Q3W 3.6 mg/kg Q3W 1:1 PHASE 1 DESIGN
Page 8
8 8 Baseline Characteristic HNSCC Cervical Median age (range) 62 (24–78) 54 (32–78) Sex (M/F) 89.3% / 10.7% NA / 100% ECOG PS** 0, 1, 2 47%, 52%, 1% 44%, 56%, 0% Weight in kg mean (range) 75.2 (41.3–132.8) 64.3 (39.0–99.0) Prior therapies median (range) 3 (1–9) 3 (1–7) Enrolled Tumor Types Safety Population Efficacy Evaluable Population Non-evaluable* Study Population treated with monotherapy CRB-701 (All tumors, all doses, parts A+B of study) 317 NA NA HNSCC (2.7 mg/kg and 3.6 mg/kg) 75 71 4 Cervical (2.7 mg/kg and 3.6 mg/kg) 72 70 2 ASCO 2026: Key characteristics & tumor types BASELINE
Page 9
9 9 TRAE n=317 (%) Grade 3 19.2% Grade 4 0.9% Grade 5 None PERIPHERAL NEUROPATHY (broad terms*) Grade 1 and 2 7.3% Grade >3 None SKIN (most common, excluding alopecia) Pruritus 14.2% Dry skin 13.2% Rash 5.7% Grade 3 - rash 0.3% Grade ≥4 None OCULAR Overall 66.2% Grade 3 12.6% Grade 4 0.3%** DISCONTINUATIONS Due to AE 2.8% Due to ocular AE 1.9% ASCO 2026: Study safety population TRAEs ≥20% (n=317) Fatigue PROPORTION OF PATIENTS (%) Dysgeusia Alopecia Keratitis SAFETY
Page 10
10 10 ASCO 2026: Safety Summary (TRAEs, N=317) • Only 1 in 4 patients experienced skin AEs (excluding alopecia) • Just a single Grade 3 event (1/317**) and no Grade >4 • No cases of Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN) Low rates of skin adverse events • Patients with dose reductions (15.5%) • Patients with dose interruptions (37.2%) • Few discontinuations due to eye toxicities (1.9%) Eye toxicities manageable with prophylaxis and dose modification • 7.3% (all Grade 1 or 2)* Potentially best- in-class for peripheral neuropathy SAFETY
Page 11
11 CRB-701 in 2L+ Oropharyngeal Head and Neck Cancer (OPSCC)
Page 12
12 12 What is Oropharyngeal Squamous Cell Carcinoma (OPSCC)? DEFINITION HPV+ tumors (80–90% of OPSCC)1 Associated with higher Nectin-4 expression2 HPV+ selectivity seen with PADCEV® in 1L HNSCC3
Page 13
13 13 OPSCC is on the rise in the U.S. as prevalence of HPV+ in HNSCC is increasing: 11% → 57% over last 30 years OPSCC HPV+ RISING
Page 14
14 14 ↑ HPV+ Pathway ↓ HPV- Pathway Two Opposing Drivers ↑ HPV+ HNSCC (younger, non-smoking patients) ↓ HPV− HNSCC (older, heavy smoker/drinker patients) OPSCC growing in HNSCC: HPV+ incidence is growing while HPV- is decreasing Shift in sexual behavior (HPV is sexually transmitted) Tobacco control & public-health campaigns since the 1960s Oral HPV-16 transmission & persistent oropharyngeal infection Sharp decline in U.S. smoking and heavy alcohol use 0.8 2.6 4.6 5.0 2.0 1.0 1.8 1988 1997 2006 2015 2024 HPV + HPV - (1) (1) (1) (1) (2) (2) (3) U.S. Incidence per 100,000 OPSCC RISING
Page 15
15 15 Summary of OPSCC U.S. Epidemiology and Treatment Eligibility Total Prevalence: ∼114,000* Total Annual Incidence: ∼23,000* Annual Growth: ∼2% through 2040* Annual U.S. Deaths: ∼7,000** ~23 K* ~18 K* ~14 K* Total Incident OPSCC 1L 2L+ Keytruda monotherapy or Keytruda® + Platinum +/- 5FU or taxane Taxanes, cetuximab or 5FU monotherapy or in combination Incurable Setting: Recurrent locally Advanced or Metastatic Disease OPSCC
Page 16
16 16 Enrolled Tumor Types HNSCC All-comers ( n=75 ) OPSCC Subset ( n=41 ) Other HNSCC anatomical subsets ( n=34 ) Median age (range) 62 (24–78) 62.0 (36–77) 62 (24–78) Sex (M/F) 89.3% / 10.7% 90.2% / 9.8% 88.2% / 11.8% ECOG PS 0, 1, 2 47%, 52%, 1% 58.5%, 41.5%, 0% 32.4%, 64.7%, 2.9% Weight in kg mean (range) 75.2 (41.3, 132.8) 79.0 (51.8, 132.8) 70.5 (41.3, 105.2) Prior therapies median (range) 3 (1–9) 3 (1–9) 2 (1–7) HPV Status (Positive, Negative, Missing) 57.3%, 40%, 2.7% 85.4%, 14.6%, 0% 23.5%, 70.6%, 5.9% Disease status (Locally Advanced or Metastatic) 16%, 84% 4.9%, 95.1% 29.4%, 70.6% ASCO 2026: Key characteristics in HNSCC and subsets BASELINE
Page 17
17 17 HNSCC ASCO 2026: OPSCC associated with HPV positivity in our study (as expected) and higher nectin-4 levels 85% 15% 0% OPSCC HPV+ HPV- Unknown 23% 71% 6% NON-OPSCC HPV+ HPV- Unknown BASELINE Nectin-4 H score>150 1 in 3 1 in 10 Nectin-4 H score>175 1 in 4 1 in 12 Nectin-4 H score>200 1 in 6 1 in 30
Page 18
18 18 2.7 mg/kg 3.6 mg/kg cORR 20.0% (4/20) 42.9% (9/21) DCR 90.0% (18/20) 85.7% (18/21) 2.7 mg/kg 3.6 mg/kg cORR 7.1% (1/14) 0.0% (0/16) DCR 57.1% (8/14) 62.5% (10/16) ASCO 2026: CRB-701 confirmed responses favor OPSCC OPSCC ( n=41 ) EFFICACY Non-OPSCC ( n=30 )
Page 19
19 19 Subject Details WEEKS ON TREATMENT 3.6 mg/kg 2.7 mg/kg ASCO 2026: CRB-701 had longer durability in OPSCC HNSCC Complete Response Partial Response Stable Disease Progressive Disease Not Evaluable Treatment Ongoing Subject Details WEEKS ON TREATMENT 3.6 mg/kg 2.7 mg/kg HNSCC Complete Response Partial Response Stable Disease Progressive Disease Not Evaluable Treatment Ongoing OPSCC ( n=41 ) Non-OPSCC ( n=30 ) EFFICACY Endpoint (months) 2.7 mg/kg ( n=14 ) 3.6 mg/kg ( n=16 ) DoR 4.4 NA PFS 2.3 2.7 Endpoint (months) 2.7 mg/kg ( n=20 ) 3.6 mg/kg ( n=21 ) DoR 4.8 6.3 PFS 4.2 5.6
Page 20
20 20 3.6 mg/kg Q3W OPSCC ( n=21 ) Non-OPSCC ( n=16 ) cORR 42.9% 0% DCR 85.7% 62.5% DoR (months) 6.3 NA PFS (months) 5.6 2.7 % responders HPV+ 89% (8 out of 9) NA ASCO 2026: Efficacy summary at 3.6 mg/kg Q3W OPSCC is indication of choice EFFICACY Supports 3.6 mg/kg dose for registrational studies
Page 21
21 21 RP2D OPSCC population → Petosemtamab* (n=15)*** CRB-701** (n=21) Dosing regimen 1500 mg Q2W 3.6 mg/kg Q3W Efficacy (cORR) 13% (2/15) in OPSCC HPV+ only 50% (8/16) in OPSCC HPV+ only 43% (9/21) in OPSCC all types Median DoR (months) 6.2 in HNSCC 6.3 in OPSCC (ongoing) PFS (months) 4.9 in HNSCC 5.6 in OPSCC (ongoing) TRAEs Grade 3 & greater 59% in HNSCC 14.3% in OPSCC Contextualizing monotherapy CRB-701 and petosemtamab in 2L HPV+/OPSCC PEERS
Page 22
22 22 TEMPO-1 Registrational Study ELIGIBLE POPULATION Recurrent OPSCC Prior Platinum & Anti–PD-(L)1 RANDOMIZED 3.6 mg/kg dose 1:1 CRB-701 Monotherapy N≈125 INVESTIGATOR’S CHOICE Monotherapy N≈125 ADAPTIVE FEATURE Interim Analysis → Sample Size Re-Estimation Seamless Phase 2 → Phase 3 Transition PRIMARY (Accelerated Approval) ORR PRIMARY (Full Approval) OS STUDY DESIGN
Page 23
23 23 Padcev® + Keytruda® cORR All 39% (16/41) HPV+ 82% (9/11) HPV- 23% (7/30) Notes: • TRAEs ≥ Grade 3: 41% • Peripheral neuropathy: 32% 1L OPSCC potential: the precedent of Padcev® + Keytruda® in 1L Investigator-assessed cORR HPV+ cORR Peto + Keytruda®2 50% (4/8) Ficerafusp Alfa + Keytruda®3 27% (3/11) 1L POTENTIAL
Page 24
24 24 Padcev® added to the 2026 NCCN treatment guidelines* for HNSCC National Guidelines Version Swiecicki et al 2024 Swiecicki et al 2024** Padcev® 2L+ cORR All-comers 24% (11/46) Notes: • Demographics: 65% U.S. & 35% Japan • No breakdown by p16 • TRAEs ≥ Grade 3: 35% • Peripheral neuropathy: 24%
Page 25
Anticipated milestones – OPSCC NEXT STEPS First patient in TEMPO-1 registrational 2L study — Sept. 2026 Report CRB-701 + pembrolizumab data in 1L — Q1 2027 Report registrational interim 2L ORR data — Q1 2028 Potential BLA filing in 2L – mid 2028
Page 26
26 26 Cervical Cancer Acute unmet need in 2L in poorly addressed market
Page 27
27 27 Cervical Cancer: Commercial Opportunity for CRB-701 • Immigration of unvaccinated adult women • Socio-economics and vaccine hesitancy Numbers rising • Girls ages 13–15 remain unvaccinated for HPV (2022 NIH data) • Annual new cases in U.S. • 4,000 annual deaths • U.S. market for cervical cancer treatment 14,000 1 39% 3 $1.8B 4 2 CERVICAL CANCER
Page 28
28 28 FULL APPROVAL Few options for 2L cervical cancer 1L 2L Tisotumab vedotin Single-Agent Chemo Carbo + Paclitaxel +/- Beva +/- Pembrolizumab ACCELERATED APPROVAL2021 2024 CERVICAL CANCER
Page 29
29 29 Efficacy**** ORR 17.8% PFS 4.2 months OS 11.5 months Adverse event profile**** Ocular (Black Box) 55% (all grades) Peripheral neuropathy 39% (all grades) Bleeding 51% (all grades) Rash 25% (all grades) USA numbers Value R/M patients receiving 2L treatment 38%* Annual price (WAC) $466,208** Annualized sales (global) $328mm*** Tivdak® demonstrates a commercial potential that could be further improved CERVICAL CANCER
Page 30
30 30 Enrolled Tumor Types Safety Population Efficacy Evaluable Population Cervical 72 70 Baseline Characteristic Cervical Median age (range) 54 (32, 78) Sex (M/F) NA/100% ECOG PS 0, 1, 2 44.4%, 55.6%, 0% Weight in kg mean (range) 64.3 (39.0–99.0) Prior therapies median (range) 3 (1–7) ASCO 2026: Key characteristics & tumor types BASELINE
Page 31
31 31 CRB-701 ASCO 2026: Waterfall plot (N=70) Best % Change from Baseline in Sum of Diameters (%) DOSE MG/KG 2.7 mg/kg ( n=38 ) 3.6 mg/kg ( n=32 ) cCR 1 2 cORR 18.4% (7/38) 34.4% (11/32) DCR 55.3% (21/38) 75.0% (24/32) CERVICAL CANCER
Page 32
32 32 Subject Details WEEKS ON TREATMENT 3.6 mg/kg 2.7 mg/kg CRB-701 ASCO 2026: Swimmer plots (N=70) Months 2.7 mg/kg ( n=38 ) 3.6 mg/kg ( n=32 ) DoR 6.8 8.0 PFS 2.8 4.3 CERVICAL Complete Response Partial Response Stable Disease Progressive Disease Not Evaluable Treatment Ongoing CERVICAL CANCER
Page 33
33 33 CRB-701* ( n=32 ) Tivdak® ( n=253**) IC Chemo 2L+ ( n=249*** ) Mechanism Nectin-4 ADC with MMAE payload (DAR 2) Tissue factor ADC with MMAE payload (DAR 4) Anti-metabolite, cytoskeleton disruption, topoi inhibition etc. Target population 2L 2L 2L Dosing regimen 3.6 mg/kg Q3W 2 mg/kg Q3W various Efficacy (ORR)** 34.4% 17.8% 5.2% DoR months** 8.0 5.3 5.7 PFS months 4.3 4.2 2.9 OS months TBD 11.5 9.5 CRB-701 potential to differentiate from current standard of care in 2L CERVICAL CANCER
Page 34
34 CRB-913 Daily oral small molecule targeting chronic obesity management
Page 35
35 35 “Can we design a safe and tolerable CB1 inverse agonist with competitive weight loss to incretin therapies?”
Page 36
36 36 Cannabinoid Type-1 (CB1) is a well characterized receptor (GPCR) in metabolism PAPERS 10K in PubMed on CB1 and metabolism
Page 37
37 37 CRB-913 higher peripheral exposure and lower brain exposure vs. prior CB1s CRB-913 ~1/50th Brain:plasma ratio ~1/15th Brain level Rimonabant Otenabant Ibipinabant Taranabant Monlunabant ~30% Increase in peripheral levels
Page 38
38 38 CANYON-1 Phase 1b obesity results for oral small-molecule CB1 inverse agonist Data support CRB-913’s potential to deliver a novel non- incretin oral therapy for obesity Enrolled 254 patients across 15 US clinical sites • Trial representative of U.S. obesity population • BMI average of 37 kg/m2 and 71% of participants female 5% placebo adjusted average weight loss at 12 weeks (60mg) • Effect started early and deepened without plateauing • All participants completing treatment with 60 mg dose lost weight Emerging favorable safety and tolerability profile • Favorable GI tolerability profile vs. published data on GLP-1s • Psychiatric AEs in line with published data on GLP-1s
Page 39
39 39 A 12-week Phase 1b randomized double-blinded placebo- controlled study in adults with obesityStudy design All 15 sites located in US Randomization 1:1:1:1 n=254 Placebo QD 12-Week Treatment Phase ( CRB-913 or Placebo QD ) 20mg QD 20mg QD 40mg QD 20mg QD 40mg QD 60mg QD 4-week safety follow-up Weeks 2 4 12 16 Primary endpoint: Safety and tolerability Secondary endpoints: Placebo adjusted weight loss from baseline and related outcomes N=65 N=61 N=62 N=66
Page 40
40 40 Baseline demographics Baseline characteristics CRB-913 20mg ( n=65 ) CRB-913 40mg ( n=61 ) CRB-913 60mg ( n=62 ) Placebo ( n=66 ) Overall ( n=254 ) Female (%) 69.2 72.1 72.6 69.7 70.9 Caucasian (%) 67.7 65.6 75.8 54.5 65.7 Black or African American (%) 30.8 31.1 17.7 36.4 29.1 Other (%) 1.5 3.2 6.4 9.0 5.2 Average age (years) 48.8 49.1 49.5 44.3 47.9 Average Weight (Kg) 104.0 106.9 105.7 104.2 105.2 Average BMI kg/m2 37.6 38.0 37.2 37.1 37.5
Page 41
41 41 Dose-dependent weight loss at 12 weeks with no plateauing Weight loss 5.0%2.8% 3.3%
Page 42
42 42 Majority of participants lost weight on CRB-913 compared to placebo Response rate 46% 22% 6% 2% 91% 51% 18% 7% 82% 69% 33% 9% 100% 73% 44% 7% Lost Weight ≥ 2.5% from baseline ≥ 5.0% from baseline ≥ 7.5% from baseline Achievement of Weight Loss Thresholds at 12 Weeks (%) Placebo 20mg 40mg 60mg
Page 43
43 43 Comparable weight loss to oral GLP-1s at 12 weeks Link Link Weight loss vs oral GLP-1s 4 Weeks 8 Weeks 12 Weeks -1.1% -1.4% -2.1% Oral Semaglutide (25mg) Orforglipron (17.2mg) CRB-913 (60mg) 1 32 -2.6% -3.1% -3.9% Oral Semaglutide (25mg) Orforglipron (17.2mg) CRB-913 (60mg) 1 32 -4.3% -4.5% -5.0% Oral Semaglutide (25mg) Orforglipron (17.2mg) CRB-913 (60mg) 1 32
Page 44
44 44 Favorable safety profile with low discontinuations and no serious TRAEsSafety and tolerability CRB-913 20mg (n=65) CRB-913 40mg (n=61) CRB-913 60mg (n=62) Placebo (n=66) All Treatment-Emergent AEs (TEAEs) 39 (60.0%) 45 (73.8%) 45 (72.6%) 28 (42.4%) Severe TEAEs 3 (4.6%) 2 (3.3%) 1 (1.6%) 0 Severe Psych TEAEs 0 0 0 0 Severe GI TEAEs 0 0 0 0 Serious TEAEs 2 (3.1%) 1 (1.6%) 1 (1.6%) 0 All Treatment-Related AEs (TRAEs) 27 (41.5%) 34 (55.7%) 33 (53.2%) 14 (21.2%) Severe TRAEs 0 1 (1.6%) (headache) 0 0 Serious TRAEs 0 0 0 0 Treatment Discontinuations due to AEs 2 (3.1%) 8 (13.1%) 8 (12.9%) 3 (4.5%) Treatment Discontinuations due to psych AEs (all mild or moderate) 1 (1.5%) 3 (4.9%) 6 (9.7%) 1 (1.6%) Treatment Discontinuations due to GI AEs (all mild or moderate) 0 1 (1.6%) 1 (1.6%) 0 Treatment Discontinuations for any reason 10 (15.4%) 16 (26.2%) 16 (25.8%) 12 (18.2%)
Page 45
45 45 Treatment-emergent psychiatric AEs of special interest Safety and tolerability: Psych CRB-913 20mg (n=65) CRB-913 40mg (n=61) CRB-913 60mg (n=62) Placebo (n=66) Suicidality 0 0 0 0 Depressive symptoms 0 0 1 (1.6%) (moderate) 0 Anxiety 2 (3.1%) 5 (8.2%) 3 (4.8%) 3 (4.5%) Insomnia 1 (1.5%) 3 (4.9%) 0 2 (3.0%) Irritability 4 (6.2%) 5 (8.2%) 6 (9.7%) 0 • Treatment-emergent psychiatric AEs were mild or moderate with no serious or severe AEs • Placebo cohort also experienced psych AEs • Irritability was most common psych AE and all cases were mild • All cases resolved with the majority continuing treatment
Page 46
46 46 CRB-913 psychiatric TEAE profile vs published GLP-1 studies link link link Psych AE in context of GLP-1 CRB-913 (All doses) Liraglutide1 Semaglutide2 Tirzepatide3 Depressive symptoms 0%–1.6% 3.0% 2.8%–4.6% 2.0% Anxiety 3.1%–8.2% 2.7% 3.3%–7.2% 1.9% Irritability 6.2%–9.7% Not reported Not reported Not reported Insomnia 0%–4.9% 3.6% 3.4%–3.9% 2.9%
Page 47
47 47 CRB-913 (20/40/60mg) n = 188 Monlunabant1 (10/20/50mg) n = 180 Depression 0%–1.6% 3%–8% Anxiety 3.1%–8.2% 10%–27% Irritability 6.2%–9.7% 10%–17% Insomnia 0%–4.9% 7%–17% AE study discontinuation 1.5%–9.8% 13%–42% Severe psych AE None 2%–7% Unresolved psych AEs None 5%–17% CRB-913 demonstrates favorable psych safety to monlunabant in a cross-trial comparison Link Psych AEs vs monlunabant
Page 48
48 48 Treatment-emergent GI AEs of special interest Safety and tolerability: GI CRB-913 20mg (n=65) CRB-913 40mg (n=61) CRB-913 60mg (n=62) Placebo (n=66) Vomiting 3 (4.6%) 5 (8.2%) 1 (1.6%) 0 Nausea 10 (15.4%) 16 (26.2%) 14 (22.6%) 3 (4.5%) Constipation 3 (4.6%) 1 (1.6%) 3 (4.8%) 2 (3.0%) Diarrhea 14 (21.5%) 16 (26.2%) 14 (22.6%) 2 (3.0%) Treatment-emergent GI AEs were mild or moderate with no serious or severe AEs
Page 49
49 49 CRB-9131 (60mg) Oral semaglutide2 (25mg) Orforglipron3 (36mg capsule - Cohort 1) Orforglipron3 (36mg capsule - Cohort 2) Vomiting 1.6% 31% 28% 14% Nausea 22.6% 47% 41% 48% Constipation 4.8% 20% 28% 24% Diarrhea 22.6% 18% 3% 14% Potentially improved GI tolerability vs. commercial oral GLP-1s GI AE in context of oral GLP-1 GI AEs were mild or moderate with no serious or severe AEs
Page 50
50 50 Discontinuations due to AEs in line vs. oral GLP-1 class AE dropout rate CRB-9131 (60mg) Oral semaglutide2 (25mg) Orforglipron3 (36mg capsule – Cohort 1) Orforglipron3 (36mg capsule – Cohort 2) # of patients assigned drug 62 205 29 29 Duration of study 12 weeks 64 weeks 36 weeks 36 weeks Treatment Discontinuations 25.8% (placebo 18.2%) 18.1% (placebo 25.5%) 17.2% (placebo 16.0%) 20.7% (placebo 16.0%) AE Treatment discontinuation 12.9% 6.9% 10.3% 20.7% Titration Schedule 2 titrations (every 2 weeks) 3 titrations (every 4 weeks) 6 titrations (every week) 4 titrations (every 3 weeks)
Page 51
51 51 Data supports CRB 913 potential as new class of oral non-incretin obesity medicines 5% weight loss at 12 weeks with no evidence of plateauing (comparable to oral GLP-1) Psych AE profile supports benefits of peripheral restriction of CB1 therapy Favorable GI profile Competitive monotherapy & potential to evaluate in combination with GLP-1 1 2 3 Key Points: • GLP-1 comparable weight loss of 5% weight loss at 12 weeks with no evidence of plateauing • Peripheral restriction avoids psych risks of prior CB1s • Markedly better GI profile than oral GLP-1s • limited to irritability • Neuro events infrequent • Irritability is most common AE, but all are mild and did not lead to discontinuation • GI markedly better than incretins • Favorable and differentiated psych AE profile to GLP-1s
Page 52
52 52 CRB-913 moving forward → Phase 2 Anticipated next steps Present Phase 1b dataset at ObesityWeek as a late breaker Engage with FDA regarding clinical development plan Initiate Phase 2 monotherapy study in 1H 2027 Evaluate potential combination therapies
Page 53
53 53 Addressable market opportunity for CRB-913 is significant Link Link Link Monotherapy Target Markets Combination therapy Lifelong maintenance >1 billion people worldwide with obesity1 ~ 3 billion people worldwide overweight2 ~23% intolerant to incretins4 64% of GLP-1 users discontinue at 1 Yr4 ~20% non- responders4 to incretins >200 associated co- morbidities3
Page 54
54 Leadership Upcoming Catalysts
Page 55
55 55 Senior Management Team Yuval Cohen, PhD Corbus co-founder and Chief Executive Officer since 2014. Previously the President and co-founder of Celsus Therapeutics from 2005. Sean Moran, CPA, MBA Corbus co-founder and Chief Financial Officer since 2014. Prior senior financial management experience in emerging biotech and medical device companies. Ian Hodgson, PhD Dr. Hodgson joined Corbus in 2022. Previously he held senior leadership positions in biotech and contract research organizations. Most recently served as V.P., Head of Clinical Services at TMC Pharma. Leonardo Vianna Niccio, MD Nishant Saxena, MBA Mr. Saxena joined Corbus in May 2026. Most recently he was CFO at Jeune Aesthetics, Inc. and previously was a healthcare investment banker at Evercore. Dr Nicacio joined Corbus in August 2026. Most recently he was the CMO at Protara and previously was VP of Clinical Development at Seagen.
Page 56
56 56 Board of Directors Winston Kung, MBA More than 20 years of senior financial, business development and investment banking experience; currently CFO of ArriVent. (NASDAQ: AVBP) Yuval Cohen, PhD Corbus co-founder and Chief Executive Officer since 2014. Previously the President and co-founder of Celsus Therapeutics from 2005. Anne Altmeyer, PhD, MBA, MPH Greater than 25 years of experience advancing oncology R&D programs and leading impactful corporate development transactions; former CEO of TigaTx (acquired by Epsilogen Ltd.) Yong (Ben) Ben, MD, MBA 25 years of oncology R&D experience across industry and academia. CMO of BridgeBio Oncology Therapeutics and former CMO of BeiGene. John K. Jenkins, MD Distinguished 25-year career serving at the U.S. FDA, including 15 years of senior leadership in CDER and OND. Rachelle Jacques More than 30-year professional career, experience in U.S. and global biopharmaceutical commercial leadership, including multiple high-profile product launches in rare diseases; CEO of Vasque Bio and former CEO of Enzyvant Therapeutics (now Sumitomo Pharma) and Akari Therapeutics (NASDAQ: AKTX) Brent Pfeiffenberger, PharmD, MBA President and CEO of Century Therapeutics (NASDAQ: IPSC). Former SVP Head of U.S Oncology at BMS
Page 57
57 57 Anticipated corporate milestones Commence registrational study in 2L OPSCC CRB-701 + pembrolizumab in 1L OPSCC data Interim ORR readout in 2L OPSCC Potential BLA filing for 2L OPSCC September 2026 Q1 2027 Q1 2028 Mid 2028 CRB-701 Additional Phase 1b data at ObesityWeek® 2026 Initiate Phase 2 monotherapy study November 2026 1H 2027CRB-913
Page 58
58 58